During this segment, Michael A. Evans, BS, RPh, discusses the importance of initiating anticoagulation for patients at risk of developing thromboembolic complications. However, he recognizes that the costs of treating patients with anticoagulants, especially direct-acting oral anticoagulants, affect both patients and the health system.
Health systems need to have a process in place for recognizing and managing patients who are at risk for thromboembolic disease, says Mr Evans, and an appropriate management team and proper resources are essential to implementing this process.
When considering initiating treatment with an anticoagulant, healthcare professionals need to take into account the burden of cost on both patients and health systems, as high treatment cost may affect patient adherence, explains Mr Evans. Over time, cost has become more of a consideration for patients due to the introduction of the direct-acting oral anticoagulants, which are more expensive than warfarin.
Therefore, when evaluating treatment options with patients, Mr Evans suggests that healthcare professionals discuss the differences in costs between therapy options and ensure that patients are a part of the decision-making process.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More